Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 147

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 147
---
 to provide comprehensive ARS services, allowing it to meet patients’
increasing demand for advanced, high-end, and sophisticated ARS, a higher standard and a wider range of advanced services.

NewGenIvf has extensive experience
serving Asia-Pacific patients and a deep understanding of their general profiles. In particular, NewGenIvf has personnel speaking multiple
languages, including nurses, facilitators, and translators, who are familiar with the health condition and culture of Asia-Pacific patients
from different countries in the region. NewGenIvf believes that it is therefore well-positioned to benefit from market growth driven
by Asia-Pacific patients travelling to its clinics for treatment.

Attractive Market with Significant Demand and Fast Growth

NewGenIvf operates in the
ARS market in Asia Pacific, positioning it to leverage on an attractive market with compelling underlying growth potential.

Built on years of experience,
NewGenIvf has established a strong reputation in its industry, which in turn attracted potential business partners to approach NewGenIvf
to negotiate cooperations and referrals. Over the years, NewGenIvf sends representatives to medical expos mostly held in the PRC to approach
potential business partners and establish new partnerships by entering into agency agreements with each agent. NewGenIvf has become a
significant partner with approximately 90 fertility service agents in China as well as in India. Normally, each agency agreement has
a maximum term of one year, which is renewable upon mutual agreement. Agents typically market and promote NewGenIvf’s services
by word-to-mouth referrals and other measures and NewGenIvf pays the agents commission at a range of 10% to 25% of the treatment fees
upon the completion of client’s treatment. Normally, agents provide potential clients’ contact information to the sales team
of NewGenIvf, who then approach potential clients and provide consultation on services. With its partnerships in various countries, NewGenIvf
believes it is able to better benefit from the growing market opportunities.

Exclusively Owned and Licensed Technology for Family Planning and Access to Mature Fertility Technologies

NewGenIvf believes that its
licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual patient’s
needs. These technologies include:

| ● | Preimplantation Genetic                                                                                                               
 Screening (“PGS”): PGS is used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence               
 of aneuploidy (either too many